Alzheimer’s Drug Hope Dashed for NHS Patients

Imagine having a drug that could slow Alzheimer’s, but being told you can’t get it on the NHS. That’s what’s happening with two new treatments, lecanemab and donanemab. Even though they’re hailed as breakthroughs, the NHS regulator says they’re just too pricey for public use—leaving thousands of patients in limbo. Private treatment? Sure, if you’ve got £60k+ a year. This decision isn’t final yet, but it’s a huge blow for families hoping for a lifeline. #Alzheimers #NHS #HealthNews #Health #BodyHealth